Table 3.
Multivariate analysis of the prognosis of 251 patients with N0-category NPC and ENLNs using an adjusted Cox proportional hazards model
| Variable | RRFS | DFS | OS | DMFS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| Gender (male vs. female) | <0.001 | – | 0.666 | 1.548 | 0.530–4.525 | 0.424 | 1.089 | 0.223–5.307 | 0.916 | 1.562 | 0.340–7.182 | 0.567 |
| Age (≥50 vs. <50 years) | <0.001 | – | 0.583 | 2.318 | 0.998–5.386 | 0.051 | 7.955 | 1.916–33.026 | 0.004 | 2.821 | 0.892–8.919 | 0.077 |
| Smoking (yes vs. no) | 0.009 | – | 0.841 | 1.680 | 0.686–4.116 | 0.257 | 2.608 | 0.713–9.536 | 0.147 | 2.393 | 0.759–7.544 | 0.136 |
| Drinking (yes vs. no) | 0.001 | – | 0.870 | 0.350 | 0.047–2.632 | 0.308 | <0.001 | – | 0.980 | <0.001 | – | 0.985 |
| Serum LDH level (<245 vs. ≥245 U/L) | <0.001 | – | 0.857 | 4.689 | 1.370–16.050 | 0.014 | 15.445 | 3.224–73.992 | 0.001 | 5.794 | 1.258–26.693 | 0.024 |
| Family history of cancer (yes vs. no) | 132.973 | – | 0.585 | 0.764 | 0.302–1.933 | 0.570 | 0.199 | 0.034–1.172 | 0.074 | 0.602 | 0.160–2.270 | 0.454 |
| BED (<72 vs. ≥72 Gy) | 107,046.092 | – | 0.485 | 2.438 | 0.882–7.226 | 0.108 | 3.097 | 0.697–13.754 | 0.137 | 2.741 | 0.60–12.526 | 0.193 |
| Chemotherapy (yes vs. no) | <0.001 | – | 0.473 | 1.123 | 0.409–3.084 | 0.821 | 1.132 | 0.235–5.465 | 0.877 | 0.924 | 0.228–3.752 | 0.912 |
| T category (T1–2 vs. T3–4) | <0.001 | – | 0.539 | 1.204 | 0.510–2.842 | 0.672 | 2.984 | 0.649–13.720 | 0.160 | 1.497 | 0.468–4.794 | 0.497 |
| ENLN diameter (<5.5 vs. ≥5.5 mm) | <0.001 | – | 0.498 | 1.914 | 0.704–5.200 | 0.203 | 1.288 | 0.308–5.392 | 0.729 | 2.579 | 0.556–11.969 | 0.226 |
RRFS regional relapse-free survival, DFS disease-free survival, OS overall survival, DMFS distant metastases-free survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, BED biological equivalent dose
– No confidence interval